The tumour suppressor gene PTEN, located at chromosome sub-band 10q23.3, encodes a dual-specificity phosphatase that negatively regulates the phosphatidylinositol 3 0 -kinase (PI3 K)/Akt-dependent cellular survival pathway. PTEN is frequently inactivated in many tumour types including glioblastoma, prostate and endometrial cancers. While initial studies reported that PTEN gene mutations were rare in colorectal cancer, more recent reports have shown an approximate 18% incidence of somatic PTEN mutations in colorectal tumours exhibiting microsatellite instability (MSI þ ). To verify the role of this gene in colorectal tumorigenesis, we analysed paired normal and tumour DNA from 41 unselected primary sporadic colorectal cancers for PTEN inactivation by mutation and/or allelic loss. We now report PTEN gene mutations in 19.5% (8/41) of tumours and allele loss, including all or part of the PTEN gene, in a further 17% (7/41) of the cases. Both PTEN alleles were affected in over half (9/15) of these cases showing PTEN genetic abnormalities. Using immunohistochemistry, we have further shown that all tumours harbouring PTEN alterations have either reduced or absent PTEN expression and this correlated strongly with later clinical stage of tumour at presentation (P ¼ 0.02). In contrast to previous reports, all but one of the tumours with PTEN gene mutations were microsatellite stable (MSIÀ), suggesting that PTEN is involved in a distinct pathway of colorectal tumorigenesis that is separate from the pathway of mismatch repair deficiency. This work therefore establishes the importance of PTEN in primary sporadic colorectal cancer.
The tumour suppressor gene PTEN, located at chromosome sub-band 10q23.3, encodes a dual-specificity phosphatase that negatively regulates the phosphatidylinositol 3 0 -kinase (PI3 K)/Akt-dependent cellular survival pathway. PTEN is frequently inactivated in many tumour types including glioblastoma, prostate and endometrial cancers. While initial studies reported that PTEN gene mutations were rare in colorectal cancer, more recent reports have shown an approximate 18% incidence of somatic PTEN mutations in colorectal tumours exhibiting microsatellite instability (MSI þ ). To verify the role of this gene in colorectal tumorigenesis, we analysed paired normal and tumour DNA from 41 unselected primary sporadic colorectal cancers for PTEN inactivation by mutation and/or allelic loss. We now report PTEN gene mutations in 19.5% (8/41) of tumours and allele loss, including all or part of the PTEN gene, in a further 17% (7/41) of the cases. Both PTEN alleles were affected in over half (9/15) of these cases showing PTEN genetic abnormalities. Using immunohistochemistry, we have further shown that all tumours harbouring PTEN alterations have either reduced or absent PTEN expression and this correlated strongly with later clinical stage of tumour at presentation (P ¼ 0.02). In contrast to previous reports, all but one of the tumours with PTEN gene mutations were microsatellite stable (MSIÀ), suggesting that PTEN is involved in a distinct pathway of colorectal tumorigenesis that is separate from the pathway of mismatch repair deficiency. This work therefore establishes the importance of PTEN in primary sporadic colorectal cancer.
Introduction
Colorectal cancer (CRC) constitutes the second most common cause of cancer deaths in many Western countries. Colorectal carcinogenesis is a multistep process with tumours displaying considerable genetic heterogeneity. A number of genetic and epigenetic alterations resulting in the inactivation of tumour suppressor genes and/or the activation of oncogenes have been described (Ilyas et al., 1999; Chung, 2000) . Some of these molecular changes, such as mismatch repair deficiency, known to occur in 10-15% of sporadic colorectal cancers (Aaltonen et al., 1993; Ionov et al., 1993; Thibodeau et al., 1993) , have been shown to correlate with the pathological features of the tumour and clinical course of the disease (Elsaleh, 2001; Elsaleh et al., 2000 Elsaleh et al., , 2001a Watanabe et al., 2001) . The range of genetic alterations involved in colorectal carcinogenesis is incomplete and further key genes involved in the pathogenesis of CRC remain to be identified.
The tumour suppressor gene PTEN (phosphatase and tensin homologue deleted on chromosome 10) is located on chromosome sub-band 10q23.3 and encodes a dualspecificity phosphatase displaying homology to the cytoskeletal proteins tensin and auxilin (Li and Sun, 1997; Steck et al., 1997) . PTEN is a protein and lipid phosphatase whose major substrate is the second messenger phosphatidylinositol 3,4,5-triphosphate (PIP-3), produced by the activity of phosphoinositide 3-kinase (PI3K). An important downstream target of PI3K is protein kinase B (PKB)/Akt, which controls cell proliferation and protects cells from apoptosis. Loss of PTEN function results in increased PIP-3 concentration and consequent PKB/Akt hyperactivation leading to protection from various apoptotic stimuli (Downward, 1998; Maehama and Dixon, 1998; Myers et al., 1998) . PTEN is now known to function as a tumour suppressor through negative regulation of the PI3K/Akt pathway (Li et al., 1998; Stambolic et al., 1998; Wu et al., 1998) among other roles.
PTEN was considered a good candidate for involvement in colorectal tumorigenesis for a number of reasons. First, allele loss close to the PTEN locus has been reported in 30% of sporadic CRC (Frayling et al., 1997) . Second, somatic mutations or deletions of PTEN have been observed in many other sporadic cancers including glioblastoma , prostate cancer , melanoma (Guldberg et al., 1997; Whiteman et al., 2002) and endometrial cancer . Third, germline mutations of PTEN are associated with the autosomal dominant Cowden and Bannayan-Zonana syndromes Marsh et al., 1997 Marsh et al., , 1999 , characterized by multiple hamartomas of many tissues including the gastrointestinal tract. Cowden syndrome is also associated with an increased risk of breast, thyroid and endometrial neoplasia Marsh et al., 1998; Eng, 2000) . Finally, colon cancer has been described in Pten þ /À chimaeric mice (Di Cristofano et al., 1998) but is not a known component of Cowden syndrome (Eng, 2000) , although rare Cowden individuals have been found to have colorectal cancers (Eng, unpublished observations) .
Initial reports of PTEN mutation screening in sporadic CRC found somatic mutations to be uncommon (Okami et al., 1998; Wang et al., 1998; Chang et al., 1999; Negoro et al., 2000) . However, recent reports show a 17-19% incidence of PTEN mutations in microsatellite unstable (MSI þ ) colorectal tumours suggesting that PTEN mutations could be selected for during tumorigenesis, but as a later event (Guanti et al., 2000; Dicuonzo et al., 2001; Shin et al., 2001; Zhou et al., 2002b) . To verify the role of PTEN in sporadic CRC and to explore its role in MSIÀ tumours, we screened a series of 41 unselected primary sporadic colorectal tumours for PTEN mutations and deletions. We report the detection of PTEN gene mutations in 19.5% of sporadic colorectal tumours, all but one of which were microsatellite stable (MSIÀ). Furthermore, all tumours with PTEN gene alterations (mutation and/or deletion) showed a reduction or absence of PTEN expression, and this correlated clinically with later stage of disease at diagnosis.
Results

Tumour MSI status
Seven of the 41 (17%) tumours exhibited microsatellite instability (MSI þ ). Two of these were of the MSI-L phenotype (CRC 23 and 42) and five were MSI-H (CRC 7, 17, 18, 46 and 52) ( Table 1) . None of the tumours showing loss of heterozygosity (LOH) at 10q23 were MSI þ and only one of the tumours with mutations was MSI þ (CRC 17). This tumour harboured two separate mutations in exon 8, affecting both alleles. The first mutation was a frameshift mutation caused by a deletion of 4 bp (ACTT) corresponding to nucleotides 955-958 of the PTEN mRNA sequence. The second was 
PTEN mutation screening
Paired normal and tumour DNA samples from 41 unselected primary sporadic colorectal tumours were screened for mutations of the PTEN coding and flanking intronic sequences (Figure 1 ), as well as for allelic loss at the PTEN locus. A total of 10 somatic PTEN mutations and one previously reported germline polymorphism (Sato et al., 2002) were identified in 8/41 (19.5%) patients (Figure 2 ). All sequence changes were confirmed by reamplification and sequence analysis of an independent PCR product. Only one of the mutations (del 955-958) has been previously described (Rhei et al., 1997; Kurose et al., 1998; Lin et al., 1998; Ali et al., 1999; Bonneau and Longy, 2000) . Six tumours harboured two or more mutations of PTEN, affecting both alleles. One tumour (CRC 1) demonstrated loss of one allele with mutation of the remaining allele. Of the eight tumours with PTEN mutations, two (CRC 2 and 37) harboured homozygous somatic changes with the remainder having heterozygous somatic changes (Table 1) . The 10 somatic mutations were located in exons 1, 3, 5, 7 and 8 (Figure 2 ). Eight were missense, one was nonsense and one was a frameshift mutation caused by the deletion of 4 bp (ACTT) within the PTEN coding region in exon 8. This mutation was detected in two tumours (CRC 17 and CRC 48A) from unrelated patients. Five mutations occurred in exon 5 (K125E, K125X, E150Q, D153Y D153N), which encodes the phosphatase domain of the protein. Six missense mutations (K62R, Y65C, K125E, E150Q, D153Y, D153N) and one nonsense mutation (K125X) fell within the N-terminal phosphatase domain of the protein (residues 7-185). The K125E and K125X mutations lie in the core phosphatase motif HCXXGRXXR (residues 123-130). Two further missense mutations (V217A, N323K) occurred within the C-terminal domain (residues 186-351) of the protein. Representative sequences of somatic mutations are presented ( Figure 3 ).
Apart from the primary tumour, patient CRC 37 also had a coincident polyp removed at the time of surgery. The PTEN mutation, observed in exon 5 (E150Q) in the carcinoma, was not seen in the matched polyp sample from the same patient.
Loss of heterozygosity at the PTEN locus
Using an initial five polymorphic markers, allele loss at the PTEN locus was observed in eight of the 41 (19.5%) tumours ( Figure 4 ). Two tumours (CRC 12 and 14) demonstrated apparent homozygous deletion of PTEN with decreased amplification intensity of marker alleles but constant reference (b-globin exon 2) amplification intensity. CRC 12 showed homozygous deletion of the two flanking markers (D10S579 and D10S541) with all intragenic markers being noninformative. Retention of both alleles at D10S1735 defined the deletion boundary between D10S541 and D10S1735. CRC 14 showed homozygous deletion at D10S579 and AFMa086wg9 with LOH at IVS8 þ 32 T/G and retention of both alleles at D10S541 and D10S1735. Retention of heterozygosity at D10S1687 defined the boundary of deletion between this marker and D10S579. CRC 1 demonstrated LOH at two intragenic marker loci with mutation of the remaining PTEN allele. The remaining five tumours demonstrated LOH (hemizygous deletion) without mutation of the remaining PTEN allele (Figure 4 ). Combined PTEN mutation and deletion data show that of the 15 tumours with PTEN alterations (seven with mutations only, five with hemizygous deletion, two with homozygous deletion and one with concurrent LOH and mutation), both alleles were affected in over half (9/15) of the cases.
Tumour PTEN expression
Immunohistochemical analysis of normal colonic epithelium showed that PTEN expression was predominantly cytoplasmic ( þ þ immunoreactivity, n ¼ 41), (Table 2) . Tumours with suspected Figure 3 Sequence analysis of novel PTEN somatic mutations. Samples showing migration shifts (a-e) were sequenced to determine the nature of the suspected mutation. (a) Biallelic mutation of PTEN in CRC 19. Two mutations (K62R and Y65C) were detected in exon 3 of CRC 19. The mutant sequence was cloned and each mutation was found to be located in a different clone suggesting that each mutation occurred on a different PTEN allele. (b) Heterozygous somatic mutation (D153Y) in CRC 3 exon 5; (c) heterozygous somatic mutation (V217A) in CRC 3 exon 7; (d) homozygous somatic mutation (E150Q) in CRC 37 exon 5; (e) homozygous somatic mutation (D153N) in CRC 2 exon 5. G, germline or constitutional DNA; T, tumour DNA. The arrows indicate the position(s) of the sequence variation (s) homozygous deletions including PTEN showed a corresponding absence of PTEN expression (À, n ¼ 2), while tumours with hemizygous PTEN deletion all showed a corresponding decrease in PTEN expression ( þ , n ¼ 5) ( Figure 5 ). Interestingly, the homozygous deletion in CRC 12 (deleted at D10S579 and D10S541) must have included the PTEN gene as PTEN expression was absent. CRC 12 showed homozygous deletion of the two flanking markers (D10S579 and D10S541) with all intragenic markers being noninformative.
In addition, 12 tumours showed reduced or absent PTEN immunoreactivity in the absence of any PTEN genetic alteration suggesting a role for epigenetic factors affecting PTEN expression in these tumours ( Figure 5 ).
Clinicopathological correlations
Clinical characteristics were compared according to MSI status, because of the known correlations of MSI with certain clinicopathological features. MSI þ tumours were associated with being right sided and occurring in patients with younger age (P ¼ 0.03). In the 34 MSIÀ tumours, there was a significant association between reduced or absent PTEN staining in the tumour and later tumour stage (P ¼ 0.02). This was consistent with the trend seen between reduced or absent staining and incidence of death from CRC (no deaths in the 10 patients with normal tumour staining but six deaths in the 18 patients with reduced or absent staining). This association did not reach statistical significance but follow-up times were relatively short. There was a trend towards MSIÀ tumours without PTEN mutation or deletion occurring on the left side of the colon, but there was no association with sex and age of the patient, or grade of the tumour.
Discussion
This report demonstrates that the PTEN tumour suppressor is frequently altered in primary sporadic CRC. Structural PTEN abnormalities (mutation and/or deletion) were present in 37% of primary tumours and affected both alleles in over half of the cases. All but one of the tumours with PTEN mutations were microsatellite stable (MSIÀ). All tumours with structural PTEN abnormalities showed a reduction or absence of PTEN expression in the neoplastic cells, and, conversely, no tumours that retained PTEN staining harboured PTEN alterations. In contrast to MSI þ CRC, known to harbour somatic PTEN mutations, none of the mutations detected in MSIÀ CRC occurred in the coding mononucleotide tracts in exons 7 and 8 (Zhou et al., 2002a) . This suggests that the PTEN gene is involved in a distinct pathway of colorectal tumorigenesis that is separate from the pathway of mismatch repair deficiency. Interestingly, CRC 37 harboured a homozygous somatic mutation (E150Q) that was not present in the matched polyp sample of the same patient and further suggests that PTEN mutation may be involved in CRC progression.
Reduced or absent PTEN expression has previously been reported in 35% of MSI þ CRC, of which 15-20% were shown to have PTEN alterations (Zhou et al., 2002b) . In contrast, reduced expression has previously been documented in only approximately 17% of MSIÀ tumours and no structural PTEN alterations were documented in these tumours (Taniyama et al., 2001; Zhou et al., 2002b) . Complete absence of PTEN expression has not been previously reported in any MSIÀ (or MSI status unknown) colorectal cancer (Taniyama et al., 2001; Zhou et al., 2002b) and this is the first report to correlate reduced or absent PTEN expression with PTEN structural abnormalities in a significant number of MSIÀ CRC.
PTEN inactivation appears to occur through different mechanisms in different tumour types, and more than one mechanism can coexist within a single tumour type (Taniyama et al., 2001; Zhou et al., 2002b) . In our series of sporadic CRC, PTEN inactivation, with consequent reduction or absence of PTEN expression, appeared to occur by three distinct mechanisms. First, structural biallelic inactivation, through mutation of both alleles, homozygous deletion or a combination of mutation and deletion, occurred in 22% of tumours, and accounted for over half of the cases in which PTEN alterations were detected. While structural biallelic inactivation is common in glioblastoma multiforme, cervical carcinoma and endometrial cancer (Kong et al., 1997; Duerr et al., 1998; Zhou et al., 1999; Kurose et al., 2000; Mutter et al., 2000; Mutter et al., 2001 ), it has not been previously observed in CRC.
Second, monoallellic inactivation by mutation or hemizygous deletion of PTEN was found in a similar proportion (20%) of tumours in our series. Interestingly, hemizygous deletion led to reduced PTEN expression while monallelic mutation of PTEN led to either reduced or absent expression. It is possible that the remaining allele harbours a mutation occurring in a region of the gene not analysed in this study, or that epigenetic factors may be acting on the remaining allele. Interestingly, hemizygous PTEN knockout mouse models have demonstrated that loss of a single PTEN allele is sufficient for tumorigenesis (Di Cristofano et al., 1998; Stambolic et al., 1998; Di Cristofano et al., 1999; Podsypanina et al., 1999) , and hemizygous deletion of PTEN appears to be common in some tumour types such as breast and prostate cancers (Feilotter et al., 1998; Singh et al., 1998) .
We also identified a third group of tumours with reduced or absent PTEN expression but without any detectable PTEN structural genetic alterations. It is postulated that PTEN may be inactivated by epigenetic mechanisms alone, suggesting that biallelic epigenetic silencing may also be a mechanism of PTEN inactivation in sporadic CRC. Biallelic epigenetic silencing is the predominant mechanism of PTEN inactivation in metastatic melanoma and occurs in a small subset of epithelial ovarian carcinomas Salvesen et al., 2001) .
Mutations of the PTEN gene were detected in 19.5% of primary sporadic colorectal tumours (MSIÀ, n ¼ 7; MSI þ , n ¼ l). Nine novel, and one previously reported, mutations were detected in this study (Rhei et al., 1997; Kurose et al., 1998; Lin et al., 1998; Ali et al., 1999; Bonneau and Longy, 2000; Sato et al., 2002) . While PTEN mutations have been reported in 17-19% of MSI þ CRC (Guanti et al., 2000; Dicuonzo et al., 2001; Shin et al., 2001 ), they have not been previously documented in a significant proportion of MSIÀ tumours (Okami et al., 1998; Wang et al., 1998; Chang et al., 1999; Negoro et al., 2000) . Our detection of a higher frequency of PTEN mutations in sporadic MSIÀ CRC, in contrast to previous reports, may be attributed to several factors. First, the technique of dideoxy fingerprinting (ddF) for mutation screening is known to be more sensitive and less dependent on the nature of the mutation, than single-strand conformation polymorphism (SSCP) (Sarkar et al., 1992) used in all but one of the previous studies (Liu and Sommer, 1994) . Furthermore, SSCP has been shown to be highly insensitive in detecting germline PTEN mutations in Proteus syndrome (0% detection rate) . Second, our study involved microdissection of tumour specimens to minimize contamination of normal tissue DNA. Third, there may be population differences in the incidence of PTEN mutations in CRC, similar to that observed in endometrial cancer (Maxwell et al., 2000) .
Exon 5, encoding the phosphatase domain of the protein, a region crucial for tumour suppressor function, appeared to be targeted with 50% of mutations occurring in this exon. Overall, the N-terminal phosphatase domain (residues 7-185) was the site of six missense and one nonsense mutation, including the K125E and K125X mutations that lie within the core phosphatase motif of PTEN and are predicted to alter at least the lipid phosphatase activity essential for PTEN tumour suppressor function (Lee et al., 1999; Han et al., 2000) . Interestingly, codon 125, an invariant lysine residue, appears to be a target with two distinct mutations occurring at this site. Two missense (V217A, N323 K) and one frameshift mutation were located within the C-terminal domain of the protein. This region is also essential for tumour suppressor function, and partial or total absence of phosphatase activity has been demonstrated to result from amino-acid changes outside the phosphatase domain Han et al., 2000) .
The frameshift mutation (del ACTT 955-958) was observed as a heterozygous change in two tumours (CRC 17 and 48A) from unrelated patients. The deletion of 4 bp changes codon 319 to a termination codon leading to a truncated PTEN protein lacking predicted phosphorylation sites (specific tyrosine and/or serine residues) and the C-terminal C2 domain that is important for phospholipid binding (Lee et al., 1999; Miller et al., 2002) . Interestingly, one of the tumours harbouring this mutation was MSI þ (CRC 17), while the other was MSIÀ (CRC 48A). This mutation has been previously reported in endometrial cancer (Kurose et al., 1998; Lin et al., 1998) . Neither this nor the second mutation present in the MSI þ (N323 K) tumour was typical of deficient mismatch repair, suggesting that the tumorigenic mechanism involving PTEN is independent of that of mismatch repair.
Similar to the clinicopathological correlations now well established for MSI þ tumours (Elsaleh, 2001; Elsaleh et al., 2001a, b; Watanabe et al., 2001) , there may be certain characteristics associated with tumours harbouring PTEN alterations. The association between reduced or absent PTEN staining and later clinical stage at presentation is significant, and the trend towards abnormal PTEN staining and death from CRC, if verified in a large cohort, may translate into clinical use of PTEN expression to stratify prognostic groups and, hence, help to tailor adjuvant chemotherapy. The demonstration of PTEN mutations in 19.5% of sporadic colorectal tumours, and LOH in a similar proportion, with consequent reduction or abolition of PTEN expression in all cases, redefines the role of this important tumour suppressor gene in sporadic CRC, particularly MSIÀ tumours. If subsequent in vitro functional studies confirm cellular dysfunction, PTEN may become a potential therapeutic target in CRC. In vitro and in vivo demonstration of enhanced sensitivity of PTEN-deficient tumours to inhibition of the FRAP/ RAFT/TOR component of the P13K intracellular pathway by the rapamycin analogue CCI-779 has led to the postulate that such drugs may have clinical efficacy in human PTEN-deficient cancers (Neshat et al., 2001; Yu et al., 2001) . Data presented here provide a molecular basis for the inclusion of patients with CRC in clinical trials of such novel anticancer agents.
Materials and methods
Patients and tissue samples
Samples of tumour, coincident polyps, matching blood and normal colon were collected prospectively with the informed consent of patients who underwent surgery in the South Western Sydney Area Health Service during the period 2000-2002. All samples are archived in the South Western Sydney Colorectal Tumour Bank. Consecutive unselected cases were examined except where insufficient material was available. The lack of a family history of colorectal cancer or other familial cancer syndrome was ascertained by a detailed questionnaire.
In all, 41 primary colorectal cancers from 39 patients were studied. Two patients (CRC 30 and 48) had synchronous, distinct tumours (30A, 30B and 48A, 48B) at the time of surgical resection and these were treated as separate entities. Of the 39 patients, 17 were females and 22 were males; mean age at diagnosis was 67 years (s.d. ¼ 10.9 years); and the mean duration of follow-up from date of diagnosis was 1.6 years (s.d. ¼ 0.8 years). Nine patients (23.1%) had died, all from colorectal cancer, with a mean age at death of 72.0 years (s.d. ¼ 12.2 years).
Of the 41 tumours, 23 (56.1%) occurred on the right side of the colon and 18 were left sided. Clinical stage and histological grade were classified by standard criteria (Beahrs, 1997) . Two tumours were grade 1, 31 tumours were grade 2 and eight tumours were grade 3. Clinical staging at the time of diagnosis was classified as Stage I-IV, with 18 tumours being Stage I and II (early stage) and 23 tumours being Stage III and IV (late stage).
Fresh tissue samples of tumour and normal colonic epithelium (distant to the tumour site) were snap frozen in liquid nitrogen and stored at À801C. Histological sections of a region immediately adjacent to the tumour sample taken for storage were processed for diagnostic purposes and reviewed by a dedicated histopathologist (CJH). For mutation screening, frozen sections (15 mm) were prepared from stored tumour specimens. Manual microdissection was carried out on unstained slides under low-power light microscopy ( Â 20-40) by scraping of individual cell populations with a 28-gauge needle.
DNA extraction
DNA was isolated from microdissected tumour cells and specimens of normal colonic mucosa using the RapidGene genomic DNA purification kit (Amresco) or the Qiagen DNA Mini system (QIAGEN), according to the manufacturer's instructions. DNA was extracted from peripheral blood leucocytes using the DNA isolation kit for mammalian blood (Roche Molecular Biochemicals).
Analysis of MSI status
Paired tumour and constitutional DNA samples were analysed using a panel of 10 microsatellite markers as previously described (Kahnoski et al., 2003) . Samples were classified as MSI-L (low-level microsatellite instability) if instability was observed at 20-40% of loci assayed or MSI-H (high-level microsatellite instability) if instability was observed at over 40% of loci assayed (Boland et al., 1998) .
Amplification of the PTEN coding region
The entire PTEN coding and flanking intronic sequences were amplified by PCR. Primers used were as described (Guldberg et al., 1997) , with the exception of exon 5, which was amplified in two overlapping segments (A and B) using the primers PTENEx5a-Fwd (5 0 -TATGCAACATTTCTAAAGTTACC-3 0 ) with PTENEx5a-Rev (5 0 -GCACATATCATTACAGTTC-3 0 ) and PTENEx5b-Fwd (5 0 -AATGGCTAAGTGAAGATGA CAA-3 0 ) with PTENEx5b-Rev (5 0 -AAGAAACCCAAAA TCTGTTTTCC-3 0 ), respectively. PCR was carried out in a final volume of 50 ml containing 25 ng DNA, 20 pmol each primer, 0.2 mM dNTPs, 1.5 mM MgCl 2 , 50 mM KC1, 10 mM Tris-HCl (pH 9.0) and 0.5 U Taq polymerase (AmershamPharmacia Biotech). An initial denaturation step (951C, 5 min) was followed by 34 cycles of denaturation (951C, 45 s), primer annealing (50-601C, 45 s) and extension (721C, 45 s). PCR was ended with a final extension (721C, 10 min) step. An aliquot of each PCR product was analysed on 2% agarose gels to check the efficiency of PCR.
Dideoxy fingerprinting analysis
Following amplification, PCR products were purified using the JetQuick PCR product cleanup system (Genomed) and amplicons were eluted in 35 ml of TE buffer (10 mM Tris-HCl (pH 8.0), 1 mM EDTA). Typically, 4 ml of purified PCR product was subjected to a manual cycle sequencing reaction (Sequitherm Excel II; Epicentre Technologies) with 20 pmol of the appropriate forward PCR primer and a single ddNTP. The sequencing reactions were carried out essentially as described by the manufacturer. Sequencing products were mixed with an equal volume of stop solution, denatured (951C, 5 min) and quick chilled on ice. An aliquot (4 ml) was electrophoresed (12 W, 221C, 4.5 h) on 0.5 Â MDE (mutation detection enhancement; FMC BioProducts) gels. Products were visualized by autoradiography. Samples showing migration shifts were selected for sequencing analysis (Applied Biosystems ABI 377 at the Westmead Sequencing Facility or ABI 3700 at the Sydney University and Prince Alfred Macromolecular Analysis Centre (SUPAMAC), Australia) using the amplification primers. All products were sequenced in both directions and mutations verified on both DNA strands. Samples with sequence variations were reamplified and resequenced from a second independent PCR product to ensure reproducibility of detected sequence changes.
Determination of the allelic distribution of individual mutations
Where more than one mutation occurred in an individual exon, the particular exon was reamplified and cloned using the TOPO TA cloning system (Invitrogen). Where mutations occurred in more than one exon of the gene in the same tumour, RT-PCR amplification of a region encompassing all mutations was carried out and the RT-PCR product cloned using the same system. Total RNA was isolated from microdissected tumour cells using the High Pure RNA Tissue kit (Roche Molecular Biochemicals) according to the manufacturer's instructions. Total RNA was reverse transcribed and amplified using the Superscript One Step RT-PCR system (Gibco BRL) as described by the manufacturer. RT-PCR was used to amplify the complete PTEN open reading frame using the primers PTENExl-Fwd (5 0 -ATGA-CAGCCATCATCAAAGAG-3 0 ) and PTENEx9-Rev (5 0 -GA CTTTTGTAATTTGTGTATGC-3 0 ). The RT-PCR products were subsequently purified, cloned and sequenced. In each case, 10 clones were sequenced to determine the allelic distribution of detected mutations.
Analysis of LOH at the PTEN locus
Allelic loss at the PTEN locus was determined using the markers D10S1687, D10S579, D10S541 and D10S1735, which flank the PTEN gene, as well as three intragenic markers: AFMa086wg9 (intron 2), IVS4 þ 109 ins/del TCTTA and IVS8 þ 32 T/G. Initially, five markers were analysed (D10S579, AFMs086wg9, IVS4, IVS8, D10S541) in all samples. Those samples showing allele loss at the extreme centromeric or telomeric markers were analysed with a further two markers (D10S1687 and D10S1735) to define the deletion boundaries. Marker positions and primer sequences were obtained from the Genome Database. Primers for the amplification of IVS4 þ 109 ins/del TCTTA and IVS8 þ 32 T/ G were as described by Zhou et al. (2000) and Hansen et al. (2001) , respectively. After amplification, the IVS4 þ 109 ins/ del and IVS8 þ 32 T/G genotypes were determined by differential digestion of the respective PCR products with the restriction endonucleases AflII and HindII (Roche Molecular Biochemicals), respectively Zhou et al., 2000) .
Each of the markers D10S1687, D10S579, D10S541, D10S1735 and AFMa086wg9 were coamplified with an internal standard to monitor amplification efficiency. A 280 bp region containing exon 2 of the b-globin gene was coamplified using the primers BGE2-Fwd (5 0 -CTCTGCCTATTGGTC-TATTTTCCC-3 0 ) and BGE2-Rev (5 0 -GAAAACATCAA-GGGTCCCATAGAC-3 0 ). Amplification was performed in a final volume of 25 ml containing 25 ng genomic DNA, 20 pmol each respective primer (forward primers were either 5 0 -HEX or 5 0 -FAM labelled), 0.2 mM dNTPs, 50 mM KC1, 10 mM TrisHCl (pH 8.3), 1.5 mM MgCl 2 and 0.5 U Taq polymerase (Amersham-Pharmacia Biotech). PCR was initiated by a 5 min denaturation (941C) followed by 28 cycles of denaturation (941C, 45 s), primer annealing (50-601C, 45 s) and extension (721C, 45 s). PCR cycling was ended with a 10 min extension (721C) step. Fluorescently labelled products were then electrophoresed on an Applied Biosystems ABI 3700 system (SUPAMAC, Australia). Analysis of peak signal areas, corresponding to fluorescence intensity, was carried out using the GeneScan 3.1 analysis software (Applied Biosystems). Allele loss was defined according to the following formula: LOH index ¼ (T2/T1)/(N2/N1), where T was the tumour sample, N was the matched normal sample, 1 and 2 were the intensities of the smaller and larger alleles, respectively (Giraud et al., 1997) . Loss of an allele was established if the ratio was o0.67 or 41.3. Samples were scored as showing LOH if allele loss was observed at two or more of the five initial marker loci analysed.
PTEN immunohistochemical analysis and scoring
Immunohistochemical staining was carried out on histological sections using the PTEN monoclonal antibody 6H2.1 (Cascade Bioscience, USA) that has been used by various investigators (Perren et al., 1999; Gimm et al., 2000; Zhou et al., 2000 Zhou et al., , 2002b . Essentially, tissue sections (3 mm) were deparaffinized by soaking in xylene and hydrated by passing through a graded series of ethanol. Antigen retrieval was carried out by incubation of the slides (991C, 40 min) in target retrieval solution (DAKO). Endogenous peroxidase was quenched by soaking the slides in 3% hydrogen peroxide for 5 min. Automated immunohistochemical staining was carried out using a DAKO immunoautostainer (Universal Staining System). The slides were sequentially incubated with a dilution (1 : 300) of the PTEN primary antibody, biotinylated secondary antibody (DAKO) and peroxidase-labelled streptavidin reagent (DAKO). All incubations were performed at room temperature. Finally, 3 0 -3 0 -diaminobenzidine (DAKO) was used as the coloured chromogen which gives a brown product. The slides were counterstained with Harris haematoxylin. Vascular endothelium, present in all sections, served as an internal positive control to monitor variation and act as a reference for determining intensity of staining in each slide as previously described (Perren et al., 1999; Gimm et al., 2000; Zhou et al., 2000 Zhou et al., , 2002b . Negative controls were slides treated identically to the tumour sections with the exception that they were incubated with a negative control reagent (DAKO) instead of the primary PTEN antibody.
Four independent observers (CE, CDM, XW and CJH) reviewed the slides and determined the immunostaining patterns and staining intensities of all slides blindly (with no prior knowledge of PTEN gene alteration status). Scoring was concordant in over 95% of cases, and where opinions differed, slides were re-reviewed and a consensus score applied. Immunostaining intensity of the vascular endothelium was scored as þ þ . Staining intensities equal to that of vascular endothelium were scored as þ þ (normal or retained); weak or decreased staining intensity as þ (reduced); and no immunostaining as À (absent). Immunostaining intensity stronger than that of vascular endothelium was operationally graded as þ þ þ (increased).
Statistical analyses
Analyses were conducted for all tumours and for the subgroup of MSIÀ tumours. Continuous variables were compared using the t-test. Associations between categorical variables were determined by the w 2 test or the Fisher's exact test when subgroup numbers were low. All analyses were conducted using SAS version 8 (SAS Institute Inc., Cary, NC, USA). A P-value of p0.05 was taken as denoting statistical significance.
